From the publishers of JADPRO

DLBCL Resource Center

Advertisement

Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma

Last Updated: Friday, February 11, 2022

This New England Journal of Medicine article, published after the presentation of the data at the 2021 American Society of Hematology Annual Meeting, provides more information on the phase 3 POLARIX trial of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone compared with R-CHOP among patients with previously untreated intermediate-risk or high-risk DLBCL.

New England Journal of Medicine
Advertisement
News & Literature Highlights

Medpage Today

New antibody-drug conjugate OK'd in DLBCL

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

American Journal of Hematology

2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management

Leukemia

Treatment resistance in diffuse large B-cell lymphoma

Blood Advances

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

OncoImmunology

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma

Cancers

Male and female fertility: Prevention and monitoring Hodgkin’ lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi

Blood Advances

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Annals of Medicine

Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

Clinical Lymphoma, Myeloma & Leukemia

Updated results from a rapcabtagene autoleucel (YTB323) phase I study demonstrate durable efficacy and a manageable safety profile in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Advertisement
Advertisement